HCM
TGTX icon

Highbridge Capital Management’s TG Therapeutics TGTX Stock Holding History

Highbridge Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-127
Closed -$3K – 129
2020
Q3 		$3K Hold
127
– – ﹤0.01% 84
2020
Q2 		$2K Hold
127
– – ﹤0.01% 81
2020
Q1 		$1K Buy
+127
New +$1.6K ﹤0.01% 86

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's TGTX Position: Q4 2020 in Review

Highbridge Capital Management sold out of TG Therapeutics (TGTX) in Q4 2020, closing a stake of 127 shares — an estimated $3K sold.

Highbridge Capital Management first reported a position in TGTX in Q1 2020 and held it in 3 quarters. The position peaked at $3K in Q3 2020. 247 funds tracked by Wall St. Rank hold TGTX as of Q4 2020.

  • Highbridge Capital Management reported no remaining TG Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Highbridge Capital Management sold 127 TG Therapeutics shares in Q4 2020, an estimated $3K.
  • Highbridge Capital Management first reported a position in TG Therapeutics in Q1 2020 and held it in 3 quarters.
  • Highbridge Capital Management's TG Therapeutics position peaked at $3K in Q3 2020.
  • 247 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2020.

Based on Highbridge Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.